Home Alzheimer’s Disease Brain Metastases in EGFR+ NSCLC Show Reduced Volume With Osimertinib

Brain Metastases in EGFR+ NSCLC Show Reduced Volume With [11C]Osimertinib

Reduction in the total brain metastases volume in patients with EGFR-mutant non–small cell lung cancer (NSCLC) following rapid, high, and uniform brain exposure of oral [11C]osimertinib was observed in the phase 1 ODIN-BM study (NCT03463525), results of which were reported during the 2020 World Conference on Lung Cancer Singapore.

Regarding [11C]osimertinib uptake, uniform brain distribution was recorded in all patients at all 3 time points with PET exams after intravenous (IV) microdose administration (n = 4). MRI also illustrated reductions in total brain metastases volume (range, 55%-95%) after 3 to 4 weeks of treatment with oral osimertinib (Tagrisso). T1-weighted MRI scans also illustrated tumor reductions after 35 days of treatment with oral osimertinib in 1 patient.

“These data support uniform brain distribution of osimertinib in patients with NSCLC and brain metastases,”…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Toni Choueiri, MD, on What Multidisciplinary Stakeholders Should Know About CheckMate 9ER

Results from the phase 3 CheckMate 9ER trial (NCT03141177) presented at the American Society of Clinical Oncology (ASCO) 2021 Genitourinary Cancer Symposium revealed that...

Robert J. Motzer, MD, on the Rationale for the Phase 3 CheckMate 9ER Trial in Advanced RCC

Compared with sunitinib (Sutent), combination treatment with nivolumab and cabozantinib demonstrated improved efficacy and prolonged survival among patients with previously treated advanced renal cell...

PHERGain II Trial Launched to Examine Chemotherapy-Free Treatment for Patients With HER2+ Breast Cancer

A clinical trial to support the use of a chemotherapy-free therapeutic approach has been launched and will aim to demonstrate that this approach is...

FDA Grants Breakthrough Therapy Designation to Tipifarnib for Treatment of HRAS-Mutant HNSCC

The FDA has granted breakthrough therapy designation to the investigational drug tipifarnib for the treatment of patients with recurrent or metastatic HRAS-mutant head and...

Recent Comments